Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

Study validates Ibex Breast solution

July 2025—Ibex Medical Analytics reports that a study conducted at Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution, significantly improves accuracy and efficiency in evaluating breast pathology cases (Tahir M, et al. Clin Breast Cancer. Published online March 26, 2025). The study analyzed 104 real-world breast biopsies, including invasive and microinvasive carcinomas, ductal carcinoma in situ, atypical lobular hyperplasia, and other benign lesions. Three breast pathologists independently reviewed each case digitally, with and without the support of Ibex Breast. Results demonstrated that when using AI, diagnostic accuracy improved from 97.1 percent to 100 percent, with previously missed precancerous lesions, such as lobular neoplasia and microcalcifications, correctly identified.

FDA clears Liaison Plex Gram-positive blood culture assay

July 2025—Diasorin has received 510(k) clearance from the FDA for its Liaison Plex Gram-positive blood culture assay. The assay detects 17 targets (13 Gram-positive bacteria and four relevant resistance gene targets) in less than two hours and features Diasorin’s proprietary NanoGrid technology, which allows the detection of nucleic acids without the need for conventional amplification reactions.

BD launches FacsDiscover A8 cell analyzer

July 2025—BD announced the worldwide commercial launch of its FacsDiscover A8 cell analyzer. It features BD SpectralFX technology, which maximizes the number of colors that can be used in flow cytometry; BD CellView image technology, which enables high-speed fluorescent and label-free imaging of single cells; and intuitive software workflows that allow for effective management of large data sets. The analyzer pairs with BD FacsDiscover cell sorters and BD reagents.

FDA clears Sysmex CN-6000 automated blood coag analyzer

July 2025—Sysmex America has received FDA clearance for its CN-6000 automated blood coagulation analyzer. The clearance also covers reagent products for prothrombin time seconds and PT INR (Dade Innovin), activated partial thromboplastin time (Dade Actin FSL), fibrinogen (Dade thrombin reagent), antithrombin (Innovance antithrombin), and D-dimer (Innovance D-dimer). Sysmex has also received Health Canada license for the CN-6000 as well as its CN-3000 automated blood coagulation analyzer.

Empire Genomics, BioDot to launch hematology FISH probe panels

July 2025—Empire Genomics and BioDot have partnered to launch a line of hematology-focused FISH probe panels and controls. The BDot Probe line is preoptimized, ready to use, and validated for performance on the BioDot CellWriter S platform. The initial release of the panels includes targeted solutions for FISH analysis of a range of hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, chronic myelogenous leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and other common hematologic disorders.

Pillar raises $34.5 million in funding

July 2025—Pillar Biosciences announced it has finalized $34.5 million in funding, which includes a strategic investment from Illumina and structured financing from Soleus Capital, as well as investments from existing investors. The proceeds will be leveraged to advance commercial activities, including infrastructure to support biopharma partnerships, and expand adoption of its distributable clinical testing kits.

Agilent unveils InfinityLab Pro iQ series

July 2025—Agilent Technologies has launched its Agilent InfinityLab Pro iQ series of mass detectors for liquid chromatography. The series includes the InfinityLab Pro iQ and InfinityLab Pro iQ Plus and supports applications such as mass confirmation, impurity profiling, biomolecule characterization, trace contaminant detection, and compound purification. The Pro iQ system, with a mass range of m/z 2–1,600, is optimized for small molecule analysis, while the Pro iQ Plus system is engineered for high-end applications and has a mass range of m/z 2–3,000.

Qiagen plans launch of three sample prep instruments

July 2025—Qiagen plans to launch three sample preparation instruments this year and next to expand its portfolio for automated sample preparation. QIAsymphony Connect, the next generation of the QIAsymphony, is progressing toward a phased launch to selected customers this year. The system, for in vitro diagnostic use, addresses pathogen nucleic acid extraction and other applications and can process up to 96 samples at a time. It features improved automation capabilities for sample tracking and new applications, higher yield for increase in assay sensitivity, and digital connectivity.

Labcorp launches MRD, liquid biopsy solutions

July 2025—Labcorp has expanded its precision oncology portfolio with its Labcorp Plasma Detect, to help assess the risk of disease recurrence in stage three colon cancer patients, and PGDx Elio Plasma Focus Dx, a kitted, pan-solid tumor liquid biopsy test authorized by the FDA to identify patients who may benefit from targeted treatments.

ARUP launches pTau 217 blood test

July 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.

MARKETPLACE

TRENDING